Victoria Baltrus, Chief Accounting Officer at Oscar Health, Inc. (NASDAQ:OSCR), sold a total of 1,523 shares of the company’s Class A Common Stock on June 2, 2026, for a combined value of $33,416. The sales occurred within a price range of $21.74 to $22.45 per share.
The transactions involved two separate sales of Class A Common Stock. In the first instance, 1,091 shares were sold at a weighted average price of $21.74 per share. These shares were executed in multiple transactions at prices ranging from $21.03 to $22.02. Subsequently, 432 shares were sold at a weighted average price of $22.45 per share, with individual transaction prices ranging from $22.03 to $22.96.
These sales were conducted under a Rule 10b5-1 trading plan, which Ms. Baltrus established on August 8, 2025. The purpose of these transactions was to satisfy tax withholding obligations related to the vesting of previously granted equity awards. Following these sales, Ms. Baltrus directly holds 214,589 shares of Oscar Health Class A Common Stock.The insider sale comes as Oscar Health stock has declined 8.2% over the past week, though shares remain up 43% year-to-date. According to InvestingPro analysis, the stock appears undervalued at current levels, placing it among opportunities on the most undervalued stocks list. For deeper insights into Oscar Health’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available for this and 1,400+ other US equities.
In other recent news, Oscar Health Inc. reported a significant earnings beat for the first quarter of 2026. The company achieved earnings per share of $2.07, nearly doubling the forecasted $1.06, although it faced a revenue shortfall. This development highlights Oscar Health’s strong profitability metrics. Additionally, Wells Fargo upgraded Oscar Health’s stock rating from Underweight to Equal Weight, raising the price target from $11 to $20. Analyst Stephen Baxter expressed growing confidence in the exchange market trajectory for 2026, despite limited visibility beyond that period. In corporate developments, Oscar Health announced a change in Mario Schlosser’s role and compensation agreement. Schlosser, formerly the President of Technology and Chief Technology Officer, has transitioned to Co-Founder & Advisor to the CEO. He will continue to support the company’s artificial intelligence and digital health initiatives while remaining on the Board of Directors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates OSCR alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if OSCR is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?